CHMFL-ABL-039

• Description :

  CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor with the IC50s of 7.9 nM and 27.9 nM, respectively. CHMFL-ABL-039 is used in the research of chronic myeloid leukemia[1].

• UNSPSC :

  12352005

• Target :

  Bcr-Abl

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/chmfl-abl-039.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC1=CN=C(NC(C2CC2)=O)C=C1)CC3=CC=C(NC(C4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4)=O)C=C3

• Molecular Formula :

  C31H33F3N6O3

• Molecular Weight :

  594.63

• References & Citations :

  [1]Wu J, et al. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) . Cancer Biol Ther. 2019;20 (6) :877-885.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2304344-56-5]